Skip to main content
main-content

The independent medical news service

Breast cancer

01-04-2019 | Oncology | News | Article

Mesothelin-targeted CAR T-cell therapy shows promise for malignant pleural disease

Phase I results reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, point to the potential of a chimeric antigen receptor T-cell therapy directed against mesothelin in patients with malignant pleural disease.

07-02-2019 | Breast cancer | News | Article

Celecoxib may be contraindicated for some breast cancer patients

Use of the cyclooxygenase 2 inhibitor celecoxib during neoadjuvant taxane-based chemotherapy is associated with adverse survival outcomes in certain subgroups of patients with breast cancer, shows a post-hoc analysis of the REMAGUS02 trial.

01-02-2019 | Colorectal cancer | News | Article

EMA gives biosimilar bevacizumab positive opinion

Read more on this decision here

24-01-2019 | Breast cancer | News | Article

TILs linked to HER2-positive breast cancer treatment outcomes

Tumour-infiltrating lymphocytes could serve as a prognostic marker in patients with early-stage HER2-positive breast cancer being treated with chemotherapy plus trastuzumab, indicates an analysis of the ShortHER trial comparing 9 weeks of trastuzumab with the standard 1-year regimen.

13-12-2018 | Breast cancer | News | Article

Trastuzumab emtansine targets residual invasive HER2-positive breast cancer

Adjuvant trastuzumab emtansine halves the risk of invasive disease recurrence or death versus trastuzumab in patients with residual invasive human epidermal growth factor receptor 2-positive early breast cancer, researchers report.

03-12-2018 | Oncology | News | Article

Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

Read more about these approvals here

08-11-2018 | Oncology | Main feed | News

TRAIN-2 questions neoadjuvant anthracycline use for HER2-positive breast cancer

Carboplatin plus taxane neoadjuvant chemotherapy may be sufficient for women undergoing dual HER2 blockade for stage II–III HER2-positive breast cancer, findings from the TRAIN-2 study suggest.

06-11-2018 | Oncology | Main feed | News

Early risers may have reduced breast cancer risk

Women who function better earlier in the day, so-called morning people, are less likely to develop breast cancer than those who consider themselves night owls, suggests a Mendelian randomization analysis.

06-11-2018 | Oncology | Main feed | News

Run-in period may improve adherence to aspirin for chemoprevention

In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.

05-11-2018 | Breast cancer | Main feed | News

Epigenetic therapy shows promise for HR-positive advanced breast cancer

Supplementing exemestane with the selective histone deacetylase inhibitor chidamide significantly prolongs the progression-free survival of women with hormone receptor-positive, HER2-negative advanced breast cancer, phase III trial findings indicate.

25-10-2018 | Oncology | News | Article

Atezolizumab combination improves advanced TNBC survival

First-line treatment with the programmed cell death ligand 1 inhibitor atezolizumab plus nab-paclitaxel has achieved a significant progression-free survival advantage over taxane chemotherapy alone in patients with metastatic triple-negative breast cancer, research suggests.

23-10-2018 | Oncology | News | Article

Serum testing reveals tamoxifen therapy nonadherence

Serum analysis suggests that within a year of beginning endocrine therapy after early breast cancer treatment, around one in six premenopausal women are no longer adherent to tamoxifen.

12-10-2018 | Breast cancer | News | Article

Endocrine therapy impacts cardiovascular risk in women with breast cancer

Long-term use of adjuvant endocrine therapy by women with a history of nonmetastatic breast cancer can significantly alter their risk for some types of cardiovascular disease, a meta-analysis shows.

11-10-2018 | Breast cancer | News | Article

Postmenopausal weight loss linked to reduced breast cancer risk

Postmenopausal women who lose weight have a lower risk for breast cancer than those who maintain a stable weight, report researchers.

10-10-2018 | Oncology | News | Article

Short-term hospitalization, mortality risk varies by palliative chemotherapy regimen

Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.

09-10-2018 | Breast cancer | News | Article

Lurbinectedin activity shown in metastatic breast cancer

Lurbinectedin, a selective inhibitor of active transcription of protein-coding genes, has promising activity in patients with BRCA1/2-mutated metastatic breast cancer, phase II study data show.

20-09-2018 | Oncology | Main feed | News

Early atezolizumab results point to potential role in metastatic TNBC care

Phase I trial findings suggest that patients with metastatic triple-negative breast cancer might benefit from treatment with the programmed cell death ligand 1 inhibitor atezolizumab.

18-09-2018 | Oncology | Main feed | News

Durvalumab, abemaciclib approvals announced by EMA

Click through to read more

03-09-2018 | Breast cancer | News | Article

EMBRACA results demonstrate talazoparib advanced breast cancer benefits

The PARP inhibitor talazoparib extends progression-free survival and improves quality of life compared with standard chemotherapy, show findings from the phase III EMBRACA study of women with advanced breast cancer and a germline BRCA1/2 mutation.

31-08-2018 | Breast cancer | News | Article

In other news: Breast cancer treatment effects

The focus this month is on early and late treatment effects in patients with breast cancer, including effects on endometrial cancer risk, cardiotoxicity, and skin toxicity.

image credits